# Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

> **NCT00113113** · PHASE1 · COMPLETED · sponsor: **Astex Pharmaceuticals, Inc.** · enrollment: 54 (estimated)

## Conditions studied

- Tumors

## Interventions

- **DRUG:** Rubitecan

## Key facts

- **NCT ID:** NCT00113113
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00113113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00113113, "Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00113113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*